Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): A survey of physicians from accredited breast centers in the United States
Katharine Yao(NorthShore University HealthSystem), Scott H. Kurtzman(Waterbury Hospital), Richard J. Bleicher(Fox Chase Cancer Center), Meena S. Moran(Cleveland Clinic), Vered Stearns(Johns Hopkins University), Cecilia Chang(Endeavor Health), Jill R. Dietz(American College of Surgeons), James L. Connolly(Beth Israel Deaconess Medical Center), Terry Sarantou(Carolinas Healthcare System)
Cited by 11
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Prognostic Factors in Breast Cancer
|Archives of Pathology & Laboratory Medicine|2000|1.1k
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|988
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850